Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4216163
Max Phase: Preclinical
Molecular Formula: C33H33N5O3
Molecular Weight: 547.66
Molecule Type: Small molecule
Associated Items:
ID: ALA4216163
Max Phase: Preclinical
Molecular Formula: C33H33N5O3
Molecular Weight: 547.66
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2[C@H]1CC[C@H](N[C@@H](Cc2ccccc2)C(=O)O)CC1
Standard InChI: InChI=1S/C33H33N5O3/c34-31-30-28(23-11-17-27(18-12-23)41-26-9-5-2-6-10-26)20-38(32(30)36-21-35-31)25-15-13-24(14-16-25)37-29(33(39)40)19-22-7-3-1-4-8-22/h1-12,17-18,20-21,24-25,29,37H,13-16,19H2,(H,39,40)(H2,34,35,36)/t24-,25-,29-/m0/s1
Standard InChI Key: XLRGWOQAKMIFSL-QEMZJVQQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 547.66 | Molecular Weight (Monoisotopic): 547.2583 | AlogP: 6.24 | #Rotatable Bonds: 9 |
Polar Surface Area: 115.29 | Molecular Species: ZWITTERION | HBA: 7 | HBD: 3 |
#RO5 Violations: 2 | HBA (Lipinski): 8 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 1.16 | CX Basic pKa: 10.93 | CX LogP: 3.61 | CX LogD: 3.42 |
Aromatic Rings: 5 | Heavy Atoms: 41 | QED Weighted: 0.20 | Np Likeness Score: -0.33 |
1. Koda Y, Kikuzato K, Mikuni J, Tanaka A, Yuki H, Honma T, Tomabechi Y, Kukimoto-Niino M, Shirouzu M, Shirai F, Koyama H.. (2017) Identification of pyrrolo[2,3-d]pyrimidines as potent HCK and FLT3-ITD dual inhibitors., 27 (22): [PMID:29037944] [10.1016/j.bmcl.2017.10.012] |
Source(1):